Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

14 results about "Tissue factor pathway inhibitor" patented technology

Tissue factor pathway inhibitor (or TFPI) is a single-chain polypeptide which can reversibly inhibit Factor Xa (Xa). While Xa is inhibited, the Xa-TFPI complex can subsequently also inhibit the FVIIa-tissue factor complex. TFPI contributes significantly to the inhibition of Xa in vivo, despite being present at concentrations of only 2.5 nM.

Adeno-associated virus compositions having increased central nervous system, brain, and / or spinal cord enrichment

Described herein are compositions and kits comprising recombinant adeno-associated viruses (rAAVs) with increased transduction enrichment in the central nervous system, brain, and / or spinal cord. The rAAV compositions described herein encapsidate a transgene, such as a therapeutic nucleic acid. The rAAV capsid and capsid proteins described herein comprise a sequence that bind to the TEK receptor tyrosine kinase (TEK) protein and / or tissue factor pathway inhibitor (TFPI) protein to facilitate crossing the blood-brain barrier. Gene therapy using the rAAVs is described. Also described are methods of treating brain-, spinal-, and central nervous system-related diseases and conditions.
Owner:CAPSIDA BIOTHERAPEUTICS INC

Tissue factor pathway inhibitor antibody and its uses

The present invention relates to antibodies and antigen-binding fragments thereof that specifically bind to TFPI and inhibit its activity. These antibodies and fragments can be used to treat hemorrhagic disorders and shorten the clotting time.
Owner:PFIZER INC

3D printed UV crosslinking masks

Current approaches in small diameter vascular grafts for coronary artery bypass surgeries fail to address physiological variations along the graft that contribute to thrombus formation and ultimately graft failure. An interlayer drug delivery system can sustain delivery of heparin through the graft with a high degree of temporal and spatial control. A heparin-loaded gelatin methacrylate interlayer sits between a biohybrid composed of decellularized bovine pericardium and poly(propylene fumarate) and UV crosslinking is controlled via 3D printed shadow masks. The masks enable control of the resultant gelMA crosslinking and properties by modulating the incident light intensity on the graft. High doses of heparin have detrimental effects on endothelial cell function. When exposed to heparin in a slower, more sustained manner consistent with the masks, endothelial cells behave similarly to untreated cells. Slower release profiles cause significantly more release of tissue factor pathway inhibitor, an anticoagulant, than a faster release profile.
Owner:UNIV OF MARYLAND

Anti-tfpi antibody having binding specificity and use thereof

Provided are an antibody specifically binding an epitope as shown in SEQ ID NO: 1 in a tissue factor pathway inhibitor, or an antigen-binding fragment of the antibody, a nucleic acid molecule encoding the antibody, an expression vector and a host cell for expressing the antibody, and a production method for the antibody. In addition, further provided are a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and a use of the pharmaceutical composition in preparation of drugs, wherein the drugs are used for preventing and / or treating coagulation diseases of patients, such as hereditary or acquired coagulation factor deficiency, Bernard-Soulier syndrome, and Glanzmann thrombasthenia.
Owner:AMPSOURCE BIOPHARMA (SHANGHAI) INC

Tissue factor pathway inhibitor antibodies and uses thereof

The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind TFPI and inhibit an activity thereof. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting time.
Owner:PFIZER INC

Tissue factor pathway inhibitor antibodies and uses thereof

The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind TFPI and inhibit an activity thereof. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting time.
Owner:PFIZER INC

Mesenchymal stem cells and therapeutic agent for liver disease

PendingJP2025071327AMicroorganismsDigestive systemMesenchymal stem cellTissue factor pathway inhibitor
To provide a novel therapeutic agent for liver disease.SOLUTION: The present invention relates to a mesenchymal stem cell characterized by high expression of the Tissue Factor Pathway Inhibitor (TFPI). It is preferable that the mesenchymal stem cell is allogeneic and is derived from a fatty tissue. Moreover, the present invention includes a therapeutic agent for liver disease containing the mesenchymal stem cell.SELECTED DRAWING: None
Owner:ROHTO PHARM CO LTD

Stable aqueous anti-TFPI antibody formulation

The present invention relates to the field of pharmaceutical formulations of antibodies. In particular, the present invention relates to stable liquid antibody formulations and pharmaceutical formulations and uses thereof. The present invention is exemplified by an aqueous formulation of an anti-tissue factor pathway inhibitor (TFPI) antibody.
Owner:PFIZER INC

Fusion proteins of TFPI-alpha and cbp4-beta

PCT designated stageWO2025177003A1FibrinogenAntibody mimetics/scaffoldsComplement component 4Tissue factor pathway inhibitor
The invention relates to fusion proteins comprising tissue factor pathway inhibitor alpha (TFPlα) or a functional fragment thereof and, an exogenous protein S binding moiety, especially complement component 4 binding protein beta (C4BPβ), or a functional fragment thereof. The invention further relates to compositions comprising the same, as well as uses thereof, in particular to inhibit coagulation or for treating thrombotic events, vectors encoding such fusion protein and, method of production thereof.
Owner:IMPERIAL COLLEGE INNVOATIONS LTD

fusion protein of TFPIα and CBP4β

PendingCN123076606AFibrinogenPeptide/protein ingredientsForeign proteinComplement component 4
This invention relates to fusion proteins comprising a tissue factor pathway inhibitor α (TFPIα) or a functional fragment thereof and an exogenous protein S-binding moiety, particularly complement component 4-binding protein β (C4BPβ) or a functional fragment thereof. The invention also relates to compositions comprising said fusion proteins, their uses, particularly for inhibiting coagulation or for treating thrombotic events, vectors encoding such fusion proteins, and methods for their preparation.
Owner:IMPERIAL COLLEGE INNVOATIONS LTD

Antibody binding tissue factor pathway inhibitor and use of antibody

Provided is an antibody specifically binding a tissue factor pathway inhibitor in a pH-dependent manner or an antigen-binding fragment of the antibody, and also provided are a nucleic acid molecule encoding the antibody, an expression vector and a host cell for expressing the antibody, and a production method for the antibody. In addition, also provided are a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and a use of the pharmaceutical composition in the preparation of patient therapeutic drugs for preventing and / or treating diseases such as genetic or acquired coagulation factor deficiency, Bernard-Soulier syndrome, and Glanzmann's thrombasthenia.
Owner:AMPSOURCE BIOPHARMA (SHANGHAI) INC

Tissue factor pathway inhibitor antibodies and their use

Antibodies and antigen-binding fragments thereof that specifically bind and inhibit the activity of TFPI are provided. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting times. The present invention provides an isolated antibody or antigen-binding fragment thereof that specifically binds to an epitope in Kunitz domain 2 (K2) of tissue factor pathway inhibitor (TFPI).
Owner:PFIZER INC

Monoclonal antibody which targets TFPI

Disclosed is a monoclonal antibody or an antigen binding fragment thereof which targets tissue factor pathway inhibitor (TFPI), and a medical use thereof.
Owner:SUZHOU ALPHAMAB CO LTD